Finding ways to improve treatment for brain tumors by targeting immune cells
Official title: Targeting epigenetic machinery to overcome myeloid cell-mediated resistance to anti-PD-1 therapy in GBM
Funded at University of Tx Md Anderson Can Ctr · NIH-11085122 · Data updated 2026-11-12
This study is looking at how certain immune cells make it harder for glioblastoma patients to benefit from a type of treatment called anti-PD-1 therapy, and it aims to find ways to improve this treatment so that patients can have better outcomes.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | June 1, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $469,956 |
| NIH project number | 5R37CA279192-03 |
| Project ID | NIH-11085122 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma who are currently receiving or considering anti-PD-1 therapy.
✕Less likely to help
Patients with other types of brain tumors or those not eligible for anti-PD-1 therapy may not benefit from this research.
What this research studies
This research focuses on overcoming the resistance that glioblastoma (GBM) tumors have to anti-PD-1 therapy, a type of immunotherapy. It investigates how myeloid cells, which can suppress the immune response, contribute to this resistance. By targeting specific epigenetic factors that regulate these immune-suppressive myeloid cells, the research aims to enhance the effectiveness of anti-PD-1 therapy. Patients may benefit from new treatment strategies that could improve their response to existing therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with glioblastoma, potentially improving survival rates.
How similar studies have gone: Previous research has shown promise in targeting immune suppression in tumors, suggesting that this approach could be effective, although the specific focus on epigenetic regulation in GBM is relatively novel.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Goswami, Sangeeta — University of Tx Md Anderson Can Ctr
- Study coordinator: Goswami, Sangeeta
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.